TETMedical continues development of NSE-FAST, the first in-vitro diagnostic blood test for brain injury from stroke, with clinical studies underway and FDA pivotal study planned for Summer 2026. Read more on TETMedical →
TETmedical appointed diagnostics commercialization executive Arjun Ishwar as chief commercial officer as NSE-FAST advances toward pivotal study.
A peer-reviewed preclinical study found AVA-003 outperformed chlorhexidine against Candida auris on skin, advancing AvantGuard’s development program.
